Management of recalled pacemakers and implantable cardioverter-defibrillators - A decision analysis model

被引:40
作者
Amin, Mitesh S.
Matchar, David B.
Wood, Mark A.
Ellenbogen, Kenneth A.
机构
[1] Virginia Commonwealth Univ, Med Coll Virginia, Dept Internal Med, Med Ctr, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Med Coll Virginia, Div Cardiol, Med Ctr, Richmond, VA 23298 USA
[3] Duke Univ, Dept Med, Durham, NC 27706 USA
[4] Duke Univ, Ctr Clin Hlth Policy Res, Durham, NC 27706 USA
[5] Durham Dept Vet Affairs Med Ctr, Durham, NC USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2006年 / 296卷 / 04期
关键词
D O I
10.1001/jama.296.4.412
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Limited information exists to direct clinical management after an implantable device has been put under advisory. A better understanding of the risks and benefits of device replacement compared with continued clinical follow-up would be helpful to clinicians. Objective Using the tools of decision analysis, to determine the best management approach ( immediate device replacement vs continued monitoring) in the setting of a device advisory. Design A decision model was constructed to evaluate the risks and benefits associated with immediate device replacement compared with continued monitoring. Main Outcome Measures Variables considered included indications for device implantation, anticipated course following device failure, device failure rates from the advisory ranging from 0.0001% to 1.0% per year, and device replacement mortality rates ranging from 0.10% to 1.00% per procedure. Device replacement was preferred to continued follow-up when replacement led to greater patient survival. Results The decision to replace a recalled device depends primarily on the advisory's estimated device failure rate and the likely effects of device failure on mortality. Procedural mortality is an important secondary factor, while patient age and remaining generator life have the least influence on the decision. For pacemaker-dependent patients, advisory device failure rates exceeding 0.3% warrant device replacement in most situations. In patients with implantable cardioverter-defibrillators for primary or secondary prevention, a failure rate associated with an advisory of 3.0% is needed to favor replacement in most cases, decreasing to close to 1.0% as procedural mortality rates decrease to 0.1% or risk of fatal arrhythmias increase to near 20% per year. In cases of pacemaker implantation for non-life-threatening situations (eg, carotid sinus hypersensitivity), most device advisories do not warrant device replacement. Conclusions The decision to replace a device under advisory is determined primarily by the incidence of device malfunction and the likely effects of device failure. This analysis provides a framework for managing recalled devices in the context of device, patient, and institutional characteristics.
引用
收藏
页码:412 / 420
页数:9
相关论文
共 32 条
  • [1] AGGARWAL RK, 1995, BRIT HEART J, V73, P571
  • [2] Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients
    Alter, P
    Waldhans, S
    Plachta, E
    Moosdorf, R
    Grimm, W
    [J]. PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2005, 28 (09): : 926 - 932
  • [3] European Heart Rhythm Association Guidance Document on cardiac rhythm management product performance
    Auricchio, Angelo
    Gropp, Michael
    Ludgate, Susanne
    Vardas, Panos
    Brugada, Josep
    Priori, Silvia G.
    [J]. EUROPACE, 2006, 8 (05): : 313 - 322
  • [4] Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure
    Bardy, GH
    Lee, KL
    Mark, DB
    Poole, JE
    Packer, DL
    Boineau, R
    Domanski, M
    Troutman, C
    Anderson, J
    Johnson, G
    McNulty, SE
    Clapp-Channing, N
    Davidson-Ray, LD
    Fraulo, ES
    Fishbein, DP
    Luceri, RM
    Ip, JH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) : 225 - 237
  • [5] A CONVENIENT APPROXIMATION OF LIFE EXPECTANCY (THE DEALE) .2. USE IN MEDICAL DECISION-MAKING
    BECK, JR
    PAUKER, SG
    GOTTLIEB, JE
    KLEIN, K
    KASSIRER, JP
    [J]. AMERICAN JOURNAL OF MEDICINE, 1982, 73 (06) : 889 - 897
  • [6] Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure
    Bristow, MR
    Saxon, LA
    Boehmer, J
    Krueger, S
    Kass, DA
    De Marco, T
    Carson, P
    DiCarlo, L
    DeMets, D
    White, BG
    DeVries, DW
    Feldman, AM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) : 2140 - 2150
  • [7] EARLY COMPLICATIONS AFTER DUAL-CHAMBER VERSUS SINGLE CHAMBER PACEMAKER IMPLANTATION
    CHAUHAN, A
    GRACE, AA
    NEWELL, SA
    STONE, DL
    SHAPIRO, LM
    SCHOFIELD, PM
    PETCH, MC
    [J]. PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1994, 17 (11): : 2012 - 2015
  • [8] Complications arising after implantation of DDD pacemakers: The MOST experience
    Ellenbogen, KA
    Hellkamp, AS
    Wilkoff, BL
    Camunas, JL
    Love, JC
    Hadjis, TA
    Lee, KL
    Lamas, GA
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (06) : 740 - 741
  • [9] Complications associated with pectoral cardioverter-defibrillator implantation: Comparison of subcutaneous and submuscular approaches
    Gold, MR
    Peters, RW
    Johnson, JW
    Shorofsky, SR
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 28 (05) : 1278 - 1282
  • [10] GOULD PA, 2006, JAMA-J AM MED ASSOC, V295, P1907, DOI DOI 10.1001/JAMA.295.16.1907